Objective:

To provide an overview of minimally invasive glaucoma surgery (MIGS) and emphasize the critical role of the ophthalmology team in patient care and collaboration.

Key Findings:

• MIGS offers more options for managing mild to moderate glaucoma, enhancing patient compliance.
• The iStent is commonly used in conjunction with cataract surgery.
• Hydrus Microstent and MicroPulse are alternatives for patients not suitable for iStent, particularly those with specific glaucoma conditions.
• Collaboration and education among the ophthalmology team enhance patient care, but awareness of potential complications is essential.

Interpretation:

MIGS represents a significant advancement in glaucoma treatment, providing less invasive options that can improve patient compliance and outcomes, reflecting the evolving nature of the field.

Limitations:

• Potential complications associated with MIGS procedures, such as inflammation and bleeding, should be carefully considered.
• Not all patients are suitable candidates for MIGS, particularly those with advanced glaucoma or specific ocular conditions.

Conclusion:

MIGS is a promising approach to glaucoma management that requires a well-coordinated ophthalmology team to ensure optimal patient outcomes, emphasizing the need for continuous education and collaboration.